Opendata, web and dolomites

FAIR SIGNED

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FAIR project word cloud

Explore the words cloud of the FAIR project. It provides you a very rough idea of what is the project "FAIR" about.

immunomodulatory    trial    enhances    emergence    assessing    pipeline    strengthens    antibiotic    bacterial    cohorts    site    course    modalities    innovation    models    health    avenues    predict    alone    therapy    care    constitute    patients    relevance    mortality    pharmacodynamics    treatment    amr    overcome    rapid    standard    stratification    morbidity    defences    nebulization    relative    resistant    fair    enrichment    infection    outcome    flagellin    antibiotics    adjunct    biology    action    recommendations    infections    airway    aerosol    markers    treatments    preclinical    public    outcomes    nebulized    leverages    worldwide    plan    subpopulation    pharmacokinetics    acceptability    safety    resistance    industrial    validation    effectiveness    capacity    clinical    therapeutic    stakeholders    curative    trials    benefit    optimal    economic    pneumonia    drug    model    epithelial    mechanisms    gain    report    simulation    host    nebuliser    analyze    antimicrobial    faced    protection    immune    device    innate    straightforward   

Project "FAIR" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 10˙162˙903 €
 EC max contribution 10˙162˙903 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 3˙701˙150.00
2    STATENS SERUM INSTITUT DK (KOBENHAVN S) participant 2˙057˙770.00
3    ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM NL (AMSTERDAM) participant 1˙200˙170.00
4    CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS FR (TOURS CEDEX 9) participant 644˙940.00
5    FREIE UNIVERSITAET BERLIN DE (BERLIN) participant 567˙750.00
6    EPITHELIX SARL CH (PLAN LES OUATES) participant 496˙000.00
7    UNIVERSITE DE LILLE FR (LILLE) participant 380˙687.00
8    UNIVERSITY OF SOUTHAMPTON UK (SOUTHAMPTON) participant 367˙186.00
9    INSERM - TRANSFERT SA FR (PARIS) participant 300˙750.00
10    EUROPEAN RESPIRATORY SOCIETY CH (LAUSANNE) participant 235˙812.00
11    AEROGEN LTD IE (GALWAY) participant 210˙687.00

Map

 Project objective

Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization.

FAIR’s objectives are to: • develop nebulization modalities for optimal airway targeting and rapid action at the infection site • demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibiotic-resistant pneumonia • identify host immune factors required for the gain of protection with systems biology • implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation • assess nebulized flagellin’s safety in a Phase I clinical trial. • analyze the acceptability and economic relevance of the therapy • identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts.

Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAIR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAIR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More